Home

Single-investor gains big in J&J acquisition

Fri, Jan 27 2017, 03:13 PM

Rudolf Maag, an investor in the Swiss pharma company Actelion, could get more than $1.5 billion when Johnson & Johnson pays $280 a share in the largest European pharma deal in 13 years